Risk of acute myocardial infarction with NSAIDs in real world use: bayesian meta-analysis of individual patient data

Abstract

Objective To characterise the determinants, time course, and risks of acute myocardial infarction associated with use of oral non-steroidal anti-inflammatory drugs (NSAIDs). Design Systematic review followed by a one stage bayesian individual patient data meta-analysis. Data sources Studies from Canadian and European healthcare databases. Review methods Eligible studies were sourced from computerised drug prescription or medical databases, conducted in the general or an elderly population, documented acute myocardial infarction as specific outcome, studied selective cyclo-oxygenase-2 inhibitors (including rofecoxib) and traditional NSAIDs, compared risk of acute myocardial infarction in NSAID users with non-users, allowed for time dependent analyses, and minimised effects of confounding and misclassification bias. Exposure and outcomes Drug exposure was modelled as an indicator variable incorporating the specific NSAID, its recency, duration of use, and dose. The outcome measures were the summary adjusted odds ratios of first acute myocardial infarction after study entry for each category of NSAID use at index date (date of acute myocardial infarction for cases, matched date for controls) versus non-use in the preceding year and the posterior probability of acute myocardial infarction. Results A cohort of 446 763 individuals including 61 460 with acute myocardial infarction was acquired. Taking any dose of NSAIDs for one week, one month, or more than a month was associated with an increased risk of myocardial infarction. With use for one to seven days the probability of increased myocardial infarction risk (posterior probability of odds ratio >1.0) was 92% for celecoxib, 97% for ibuprofen, and 99% for diclofenac, naproxen, and rofecoxib. The corresponding odds ratios (95% credible intervals) were 1.24 (0.91 to 1.82) for celecoxib, 1.48 (1.00 to 2.26) for ibuprofen, 1.50 (1.06 to 2.04) for diclofenac, 1.53 (1.07 to 2.33) for naproxen, and 1.58 (1.07 to 2.17) for rofecoxib. Greater risk of myocardial infarction was documented for higher dose of NSAIDs. With use for longer than one month, risks did not appear to exceed those associated with shorter durations. Conclusions All NSAIDs, including naproxen, were found to be associated with an increased risk of acute myocardial infarction. Risk of myocardial infarction with celecoxib was comparable to that of traditional NSAIDS and was lower than for rofecoxib. Risk was greatest during the first month of NSAID use and with higher doses.

Corticosteroids for treatment of sore throat: systematic review and meta-analysis of randomised trials

“…Pain management with paracetamol (acetaminophen) or non-steroidal anti-inflammatory drugs (NSAIDs) therefore represents the mainstay of care 45 These drugs provide limited pain relief but also sometimes cause serious harm 67 …”

Avoid routinely prescribing medicines for non-specific low back pain

“…NSAIDs taken orally, intravenously or topically, reduce pain more than placebo in the short-term by an average 6.4 points (95% CI 2.5 to 10.3) on 100-point scale in people with acute non-specific low back pain (5 RCTs, n=814, high-quality evidence ) and 11.1 points (95% CI 8.4 to 13.8) in people with chronic non-specific low back pain (9 RCTs, n=2537, moderate-quality evidence ). The median treatment duration was 7 days (IQR 5–7). Harm : Bally et al 12 systematic review including four cohort studies and individual patient data meta-analysis of individuals taking NSAIDs in the general population (n=446 763)After adjustment for confounders including selected comorbidities, short-term use of NSAIDs at any dose for 1–7 days vs non-use was associated with increased risk of acute myocardial infarction (OR 1.24, 95% CI 0.91 to 1.82) for celecoxib, 1.48 (95% CI 1.00 to 2.26) for ibuprofen, 1.50 (95% CI 1.06 to 2.04) for diclofenac, 1.53 (95% CI 1.07 to 2.33) for naproxen ( low-quality evidence ). Absolute numbers of events were not provided.…”

Czynnik różnicowania wzrostu 15 jako biomarker w niewydolności serca

“…Również u chorych na cukrzycę leczonych statynami nie odnotowano takiego efektu [36]. Wiadomo zaś, że niesteroidowe leki przeciwzapalne (NLPZ), które powodują zwiększenie ryzyka zawału serca [37] i nasilenie objawów przewlekłej HF [38], zwiększają ekspresję GDF-15 [39] (stąd inna nazwa GDF--15: NSAID-activated protein 1).…”